DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07573163

Not yet recruitingPhase 2

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Lead sponsor

Alaa Sada

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

1

Recruiting sites

—

Enrollment

34

estimated

Study population

Hypertension, Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•Systolic BP, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07573163
Org study IDSTUDY25030073

Timeline

Milestones

Study first posted2026-05-07actual
Last update posted2026-05-07actual
Primary completion2028-07-31estimated
Study completion2028-12-31estimated
Study start2026-07estimated (month precision)

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

HypertensionObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Adults aged 18 years and older
•Diagnosis of MACS, defined as morning cortisol >1.8 mcg/dL after a 1 mg dexamethasone suppression test
•Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2017 American College of Cardiology/American Heart Association [ACC/AHA] criteria, or current use of antihypertensive medication)
•BMI ≥27
•Undergoing or having undergone adrenalectomy for the treatment of MACS

Exclusion criteria

•Bilateral adrenal lesions
•Adrenal malignancy
•Concurrent primary aldosteronism with MACS
•Current use of GLP-1 receptor agonists
•Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
•Pregnancy or breastfeeding

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Glycemic / diabetes
1
Cardiometabolic biomarkers
1
Patient-reported / QoL
1
Other (unclassified)
1

Weight & body composition

2 endpoints
Secondary/protocol endpoint

weight

Time frame:Baseline and 12 months

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

BMI

Time frame:Baseline and 12 months

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

HbA1c

Time frame:Baseline and 12 months, %

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint

Change in systolic blood pressure

Time frame:Baseline and 12 months

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

quality of life metrics

Time frame:Baseline and 12 months

SF-36 total

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

medication

Time frame:Baseline and 12 months reported in WHO defined daily doses (DDDs)

descriptive

Publications (17)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.